


CLAIMS

1. A compound of formula (I)



or a pharmaceutically acceptable salt, solvate or derivative thereof.

2. A pharmaceutical composition comprising the compound according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A compound according to claim 1 for use as a medicament.

4. A composition according to claim 2 for use as a medicament.

5. A compound according to claim 1 for use as a reverse transcriptase inhibitor or modulator.

6. A composition according to claim 2 for use as a reverse transcriptase inhibitor or modulator.


7. A compound according to claim 1 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

8. A composition according to claim 2 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

9. A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound according to claim 1.




10. A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a composition according to claim 2.

5 11. A process for preparing the compound of formula (I)



or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

10 (A) condensing a compound of formulae (II), (VI) or (VII)



15


wherein L^1 and L^2 are leaving groups;

with the compound of formula (V)

20 $H_2NNHCH_2CH_2OH$ (V)

or a salt or hydrate thereof;

(B) alkylating the pyrazole of formula (XIII)



with an alkylating agent of formula (XIV)

5

$\text{Lg-CH}_2\text{CH}_2\text{OH}$ (XIV)

or a protected derivative thereof;

(C) deprotecting a protected derivative of the compound of formula (I);


10

and optionally converting the compound of formula (I) prepared by any one of steps (A) to (C) into a pharmaceutically acceptable salt, solvate or derivative thereof.

12. A process according to claim 11 wherein L^1 and L^2 are each independently selected from $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ and $-\text{N}(\text{CH}_3)_2$.


15

13. A compound of formula (II)




20

14. A compound of formula (VI)



wherein L^1 is a leaving group.


- 5 15. A compound of formula (VII)



wherein L^2 is a leaving group.


- 10 16. A compound according to claim 14 or 15 wherein L^1 and L^2 are each independently selected from $-N(C_1-C_6 \text{ alkyl})_2$ and $-N(CH_3)_2$.

17. A compound of formula (VIII)



15


18. A compound of formula (IX)



(IX).

19. A compound of formula (XIII)

5



(XIII)